Orthofix Medical stock posts USD 0.39 loss per share in second quarter
Published on 10/17/2026 at 21:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSQuarterly loss and trading metrics
- Orthofix reported an adjusted loss of USD 0.39 per share for the second quarter ended June 30, 2026.
- Orthofix Medical is scheduled to report its next results on November 3, 2026.
- Orthofix Medical stock last traded at USD 9.38 on Nasdaq on October 16, 2026 at 4:00 p.m. EDT, down 2.19 percent versus the prior close.
- Market capitalization stood at USD 379.2 million, while the price-to-earnings ratio was minus 6.11.
Orthofix Medical reported an adjusted loss of USD 0.39 per share for the second quarter ended June 30, 2026, beating the USD 0.41 consensus estimate, according to MarketBeat on October 11, 2026. On Nasdaq, OFIX last stood at USD 9.38 on October 16, 2026 at 4:00 p.m. EDT, down 2.19 percent versus the prior close.
Second-quarter loss beats estimate
The adjusted loss was USD 0.02 per share narrower than the consensus estimate. Revenue reached USD 210.93 million in the second quarter of 2026, although that figure is not used as the article's central comparison because it was already covered in the company's recent market coverage.
Orthofix's quarterly result leaves profitability as the key operating measure. The company operates in spinal implants, biologics, bone growth stimulation, navigation technology and limb reconstruction, serving hospitals, surgeons and other healthcare providers, according to Orthofix Medical.
Price range and trading volume
The USD 9.38 price was 10.35 percent above the 52-week low of USD 8.50 and 44.79 percent below the 52-week high of USD 16.99 on October 16, 2026. Trading volume was 286,064 shares, 24.03 percent below the average volume of 376,535 shares for the same market-data snapshot.
Valuation and reporting date
Orthofix Medical had a market capitalization of USD 379.2 million and a price-to-earnings ratio of minus 6.11 on October 16, 2026. The next results date is November 3, 2026, as listed by ToAlpha.
Comparison with peers
Orthofix Medical (Nasdaq, USD): minus 2.19 percent, P/E minus 6.11, market capitalization USD 379.2 million
Stryker (NYSE, USD): plus 0.49 percent, P/E 30.53, market capitalization USD 113.0 billion
Medtronic (NYSE, USD): minus 0.73 percent, P/E 23.34, market capitalization USD 121.2 billion
Trading profile in three figures
Orthofix combines a small-capitalization profile with a negative trailing valuation ratio and a quarterly adjusted loss. Its October 16, 2026 price was materially above the yearly low but below the yearly high, while volume remained below its average.
Market context: Market report Nasdaq Composite.
